Pradaxa is a popular drug that is prescribed for people who have trouble with blood clots. Coumadin is commonly prescribed for this medical condition, but some people can’t take Coumadin. When a patient can’t take Coumadin, they are often prescribed Pradaxa, or Dabigatran. Unfortunately, there have been some pretty serious problems with this drug.
One of the problems with Pradaxa is that it is much, much more expensive than Coumadin. The difference comes to about 800% more expensive! But, most patients will tell you that if the medicine worked, it would be worth the cost. The FDA rushed approval through on Pradaxa, and now some patients are paying the price in more ways than just out of their pocket books.
Problems with this new drug first started showing up with elderly patients of age 75 and over. Patients of this age started experiencing excessive bleeding at a 3% higher rate than younger patients. Perhaps most frightening about this is that there is no reversal for Pradaxa! With Coumadin, if you start bleeding uncontrollably, the doctors can give you a reversal agent that will stop the excessive bleeding. But With Pradaxa, if you start to bleed out, no one can stop the bleeding.
One of the advantages of Pradaxa is that it does not require monitoring. Coumadin requires the patient to check in with his or her doctor on a regular basis to see if the anticoagulation factor is within safe parameters. However, with Pradaxa, there is no way to monitor the anticoagulation factor. All the doctor can do is interview the patient, and accept anecdotal evidence.
RUSH TO APPROVE
The FDA has come under criticism over the last decade for apparently rushing through approval of certain drugs. This is partly due to the fact that many people are eager to receive treatment from drugs that might either save their lives, or make their lives better. The pressure of public opinion, along with pressure from the U.S. government to justify its existence, has cause the FDA to make some mistakes in releasing certain drugs for public use.
However, European countries have banned the use of Pradaxa because of the fact that there is no antidote. The prospect of patients bleeding out, with no hope of stopping the hemorrhage, has kept Pradaxa off of the market in most European and Asian nations.
In the U.S., Pradaxa was linked to over 500 deaths prior to 2010. Most of these deaths were due to bleed out, or hemorrhage. But the deaths are just part of the story. Hundreds of other patients have received liver damage from the drug, and still others have experienced heart attacks because of Pradaxa. In addition, even if you don’t die from hemorrhage, you can suffer significant brain damage and stroke from excessive bleeding, and your central nervous system can also be damaged.
If you need to join the hundreds of others who have sued Pradaxa, contact Dan Grebel. He has a lot experience with this drug, and is a great Pradaxa lawsuit attorney